Diasome Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering hepatocyte cell drug targeting to restore hepatocyte metabolism and treat metabolic diseases. Diasome's Hepatocyte Targeting Platform reestablishes hepatocyte function, addressing the root cause of dysregulations central to major metabolic diseases such as diabetes, obesity, and dyslipidemia. Diasome aims to deliver superior patient outcomes and enhanced disease management by leveraging the hepatocyte's natural regulatory functions.
View Top Employees from Diasome Pharmaceuticals, Inc.Website | http://www.diasome.com |
Revenue | $8 million |
Funding | $4.3 million |
Employees | 10 (5 on RocketReach) |
Address | 10000 Cedar Ave, Ste 6, Cleveland, Ohio 44106, US |
Phone | (216) 444-7110 |
Technologies |
JavaScript,
HTML,
PHP
+14 more
(view full list)
|
Industry | Biotechnology, Drug Manufacturing & Research, Pharmaceuticals, Healthcare |
Competitors | BioLineRx, Can Fite BioPharma (CANFY), Corbus Pharmaceuticals, DelMar Pharmaceuticals, Pherin Pharmaceuticals, Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Diasome Pharmaceuticals, Inc. employee's phone or email?
The Diasome Pharmaceuticals, Inc. annual revenue was $8 million in 2024.
Robert Geho is the Founder, Chief Executive Officer, Director of Diasome Pharmaceuticals, Inc..
5 people are employed at Diasome Pharmaceuticals, Inc..
Diasome Pharmaceuticals, Inc. is based in Cleveland, Ohio.
The NAICS codes for Diasome Pharmaceuticals, Inc. are [32541, 3254, 325, 32].
The SIC codes for Diasome Pharmaceuticals, Inc. are [28, 283].